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　Gazi MH and Ito M have previously shown that novel monoclonal antibody (mAb) 
LAD-4 inhibited the binding of RL♂1 lymhoma cells to fibronectin (FN) in vitro and 
partially those migration to the liver in vivo. In this study, I further examined the ability 
of LAD-4 to inhibit the RL♂1 liver metastasis and to have a cytopathic effect.
　Histological examination revealed s.c. inoculation of BALB/c mice with RL♂1 
followed i.p. injection of LAD-4 inhibited liver metastasis.  Furthermore, flow cytometry 
(FCM) measurement of number of RL♂1 cells into liver confirmed LAD-4 obviously 
decreased them.  LAD-4 improved survival of mice inoculated intravenously with RL♂
1, but was not curative.  LAD-4 decreased RL♂1 proliferation in vitro.  Adsorbed LAD-4 
on the micro-plates downregulated their proliferation under serum-free conditions, but 
FN did not.  Treatment of RL♂1 with LAD-4 for 3h increased Annexin V-positive cells 
and caspase-3 activation. Moreover, FCM analysis using terminal deoxinucleotidyl 
transferase (TdT) revealed that 24h treatment of RL♂1 with LAD-4 induced apoptotic 
DNA fragmentation. Inhibition of lymphoma cell adhesion to hepatocytic FN have been 
postulated the mechanism of LAD-4-mediated inhibition of RL♂1 liver metastasis.  
However, my results suggest that LAD-4 transduces an apoptotic signal through 
crosslinking of its receptor molecules and this may be another mechanism whereby 
LAD-4 inhibits RL♂1 liver metastasis.
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INTRODUCTION
　The liver is a major site of metastasis for 
many malignant tumors. Metastasis formation 
by tumor cells is a complex process of 
successive interactions between many mole-
cules, including integrins1),2), and lymphocyte 
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function associated antigen-1 (LFA-1), which 
belongs to the β2-integrin subfamily 2), is 
involved in liver metastasis by certain 
lymphoma cells3)-5). As there is no basement 
membrane under the sinusoidal endothelium 
and hepatocytes express FN on their surfaces1), 
if lymphoma cells express FN receptors, the 
FN/FN receptor interaction may also be 
involved in the liver metastasis. 
　Recently, Gazi MH and Ito M developed a 
mAb, LAD-4, that inhibits the binding of RL♂
1 lymphoma cells to FN in vitro and partially 
inhibits RL♂1 cell migration to the liver6). The 
molecular weight of the antigen recognized by 
LAD-4 is approximately 55 kDa, which differs 
from those of known any FN receptors6). 
Therefore, this antigenic molecule appears to 
be a new FN receptor.  As the ability of a tumor 
cell to migrate to a target organ does not 
correlate with its ability to metastasize in that 
organ7)-9), I examined whether LAD-4 can 
inhibit liver metastasis by RL♂1 cells. 
Accumulating evidence indicates that the 
integrin family of cell adhesion receptors can 
transduce biochemical signals to modulate cell 
growth and differentiation10). Therefore, in this 
study, I investigated whether LAD-4 had a 
cytopathic effect on RL♂1 cells and the 
mechanisms whereby LAD-4 inhibits liver 
metastasis by RL♂1 cells.  I found that LAD-4 
induced apoptosis of RL♂1 cells in vitro. Other 
possible mechanisms responsible for the 
inhibition of liver metastasis by LAD-4 are 
discussed.
MATERIALS AND METHODS
　The following investigations were performed 
under the protocol approved by the Animal 
Research Laboratory of Yamagata University 
School of Medicine. 
Animals and Cell Lines.
　BALB/c mice and BALB/c nude mice, 6-8 
weeks of age, were purchased from Japan SLC 
Inc. (Hamamatsu, Japan) and kept in the 
facilities at Animal Research Laboratory of 
Yamagata University School of Medicine. T cell 
lymphoma cell line derived from BALB/c mice, 
RL♂1, was obtained from National Cancer 
Institute (Bethesda, MD) and maintained in 
our laboratory with culture medium: RPMI-
1640 (Gibco BRL, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine 
serum (Whittaker Bioproducts, Walkersville, 
MD), 50μg/ml of gentamycin as reported 
previously6),11). Ascites cell line of RL♂1, the 
single lot stored in liquid nitrogen in 198012) 
was used for in vivo experiments described 
below.
Antibodies. 
　Rat mAb specific for CD44 (IM7) and 
phycoerythrin (PE)-conjugated streptavidin 
were purchased from BD PharMingen (San 
Diego, CA). Peroxidase-conjugated mouse IgG 
specific for rabbit IgG was from Jackson 
ImmunoResearch Laboratory (West Grove, 
PA). Rat hybridoma cell line producing anti-
LFA-1 (M17/4) was obtained from American 
Type Cell Collection (Rockville, MD). LAD-4 
and anti-LFA-1 mAb were purified from ascites 
on a protein G-Sepharose column (Amersham 
Pharmacia, UK) as reported previously6). 
In Vivo Experiments. 
　Mice were injected with 2×105 RL♂1 cells 
either s.c. in the dorsal flank or i.v. into the tail 
vein, and then received i.p. 200μg of LAD-4, 
anti-LFA-1 mAb, or normal rat IgG. The 
efficacy of mAb administration was evaluated 
by the prolongation of mean survival time of 
tumor bearing hosts, which were observed for 
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23 to 27 days.
Histological Examination.
　Mice (5 mice per group) were sacrificed at 3 
weeks postinjection and examined for the 
presence of lymphoid tumors at necropsy. 
Liver, kidneys, spleen, and lungs were removed 
and fixed in 10% formalin and embedded in 
paraffin, and 3μm sections (4 per liver) were 
stained with hematoxilin and eosin. The liver 
samples were subjected to microwave treat-
ment and stained immunohistochemically 
using peroxidase-conjugated anti proliferating 
cell nuclear antigen (PCNA) (PC10, DACO, 
Copenhagen, Denmark) antibody as described 
elsewhere13). The images of each section (100 
fields per liver) were captured by a digital still 
camera (FUJIFILM, Tokyo, Japan). The 
number of lymphoma cells, estimated by 
PCNA positivity and nuclear size, was 
measured by a computer-associated image 
analysis system using NIHimage software. The 
experiment was repeated at least three times.
Flow Cytometric Analysis.
　Cell suspensions were prepared from liver 
using a glass homogenizer and then overlayed 
on a 60% solution of Percoll (Amersham 
Pharmacia) to remove hepatocytes and red 
blood cells. After centrifugation at 400×g for 
20 min, cells of the interface were collected and 
washed with culture medium. The cells were 
incubated with biotynilated LAD-4 that was 
made according to the manufacturer's instruc-
tions (Pierce Chemical Co., Rockfold, IL). 
After 60 min on ice, cells were washed with 
PBS and subsequently incubated with PE-
conjugated streptavidin for 30 min on ice. 
After washing with PBS, the cells were 
analyzed using a FACSCalibur flow cytometer 
(Becton Dickin-son). Prior to the analysis, the 
gate was set using the mixture of ascites-line 
RL♂1 cells and spleen cells according to 
forward and side scatter. The experiment was 
repeated once with similar results. 
In Vitro Experiments.
　The culture cell line of RL♂1 was used for 
following in vitro experiments.
Measurement of Cell Growth.
　Growth of RL♂1 cells was determined by 
use of a colorimetric assay using a WST-1 
tetrazolium salt reagent (TaKaRa Biomedicals, 
Tokyo, Japan). 1-2×105 cells were cultured in 
100μl of culture medium with various doses of 
normal rat IgG, LAD-4, or anti-LFA-1 mAb. 
After 24h or 48h at 37℃, 10μl of WST-1 
reagent was added to each well of a 96-well 
tissue culture plate (Coster, Cambridge, MA) 
and allowed react for 1.5 h at 37℃.  Substrate 
cleavage was monitored at 450 nm by use of a 
Model 450 microplate reader (Bio-Rad Labora-
tories, Hercules, CA) and analyzed using a 
Microplate Manager software (Bio-Rad). In 
some experiments, 2×105 cells were cultured 
in a well of microtest plate coated with human 
fibronectin (Sigma), human laminin (Sigma), 
or LAD-4 in a serum free medium: RPMI-1640 
containing 2 % bovine serum albumin (Sigma). 
Prior to this assay, cells were stimulated with 
PMA and ionomycin for 10 min at 37℃ as 
described previously6). After 24h of incubation, 
growth of cells was determined as described 
above.  The experiment was done in triplicate 
and repeated at least three times.
Annexin V staining
　Phosphatidylserine expression on early 
apoptotic cells14) was measured by the binding 
of Annexin V using Annexin V-FITC kit 
(Beckman Coulter). 5×106 of RL♂1 cells were 
cultured in 4 ml culture medium in the 
presence of LAD-4, anti-CD44 mAb, or normal 
rat IgG (final concentration: 20μg/ml) for 3h 
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at 37℃. After incubation, the cells were 
collected and stained with FITC - labeled 
Annexin V and propidium iodide (PI) under 
the manufacturer’s instructions. The cells 
were analyzed with a FACSCalibur flow 
cytometer. The experiment was repeated once 
with similar results.
Measurement of Caspase-3 Activation.
　Caspase-3 like protease activity in cells was 
analyzed by use of a CPP32/Caspase-3 
colorimetric protease assay kit (Chemicon 
International Inc., Temecula, CA).  5×106 RL
♂1 cells were cultured in 4 ml culture medium 
with LAD-4, control antibody, or cyclophospha-
mide (Sigma) for 3h or 24h. After washing with 
PBS, cell lysate was prepared as descried by 
Nicholson et al.15). Protein concentrations were 
determined using a protein microassay (Bio-
Rad, Tokyo, Japan). The cell lysate (25μg 
protein) was mixed with 400μM of the 
caspase-3 specific substrate (DEVD-para-
Nitroanilide) in the abscence or presence of 
caspase-3 inhibitor (Ac-DEVD-CHO) and 
incubated at 37℃ for 2h. Subsequently, 
substrate cleavage was monitored at 405 nm. 
To determine specific caspase-3 activity, the 
value of the absorbance signal of the inhibitor 
sample was subtracted from that of the 
noninhibited sample.　The experiment was 
done in duplicate and repeated three times.
Western Blotting. 
　Immunodetection of proteins separated by 
SDS-PAGE and transfered to polyvinylidene 
difluoride (PVDF) membrane (Bio-Rad) was 
performed with enhanced chemiluminescence 
Western blotting reagents (New England 
Nuclear, Boston) as described previously6). 5× 
106 cells were cultured with LAD-4 (20μg/ml) 
at 37℃ for various time (0.5h to 3h). After 
washing with PBS, cells were extracted in a 
lysis buffer: 50 mM Pipes NaOH pH 6.5 with 2 
mM EDTA, 0.1% CHAPS, 5 mM DTT, 10μM 
APMSF (Wako Pure Chemical Industries, 
Osaka, Japan). Samples were adjusted to equal 
concentration and volume. Each sample 
(40μg) was separated by SDS-PAGE on 5-20% 
gels and electroblotted onto PVDF membrane. 
Rabbit polyclonal antibodies to caspase-3 
(Santa Cruz Biotechnology Inc., Santa Cruz, 
CA) and cleaved caspase-3 (Cell Signaling 
Technology, Beverly, MA) were used as primary 
antibodies. The experiment was repeated once 
with similar results.
Detection of apoptotic DNA fragmentation.
　2×106 cells were cultured in 4 ml of culture 
medium containing LAD-4 or control antibod-
ies for 3h or 24h. The cells were treated with 
TdT and stained with FITC-labeled dUTP 
under manufacturer’s instructions (Beckman 
Coulter). The stained cells were then analyzed 
using a FACSCalibur flow cytometer (Becton 
Dickinson). The experiment was repeated 
three times with similar results.
Statistical Analysis.   
　Differences between the experimental re-
sults were evaluated by means of one factor 
ANOVA with Scheffe’s F test. All values were 
expressed as mean±SD, and statistical 
significance was set at P<0.05.
　Kinetics of survival were evaluated by 
Breslow-Gehan-Wilcoxn test.
RESULTS
　As Gazi MH and Ito M have demonstrated 
that LAD-4 inhibited migration of RL♂1 cells 
into the liver6), I performed a series of 
experiments to determine whether LAD-4 
could inhibit liver metastasis and prolong 
survival of mice inoculated with lymphoma 
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cells in vivo.
Effect of LAD-4 Administration on Liver
Metastasis.
　BALB/c mice were injected s.c. with 2×105 
RL♂1 cells, followed 30 min later by i.p 
injection of 200μg normal rat IgG, anti-LFA-1 
mAb (M17/4) or LAD-4.  On day 21, the mice 
were killed and their livers were removed for 
histological examination as follows. Sections (4 
per liver) were immunostained with the anti-
PCNA antibody (Fig.1A) and, the labeled cells 
were counted using computer-associated image 
analysis. LAD-4 as well as anti-LFA-1 mAb 
significantly inhibited liver metastasis by RL♂
1 cells (Fig. 1B).  Due to the heterogeneity and 
scattered distribution of metastasis within the 
liver, histological examination of several 
sections may not reflect whole liver meta-
stases. So, to overcome this weakness, I tried to 
quantify whole liver metastasis by FACS 
analysis. Single-cell suspensions were prepared 
from each liver, immunostained with biotiny-
lated LAD-4, and analyzed by FACS, which 
gated live cells according to their forward and 
side scatter. Scatter analysis revealed that RL♂
1 cells were distributed in gate R1, whereas 
infiltrating lymphocytes in gate R3, and cell 
　Fig. 1. 
Histological analysis of the liver metastasis by 
RL♂1 cells.
BALB/c mice (5 mice per group) were inoculated 
s.c. with 2×105 RL♂1 cells and injected i.p. 
either with 200μg of normal rat IgG, LAD-4, or 
anti-LFA-1 mAb (M17/4). On day 21 after tumor 
inoculation, mice were sacrificed and histologi-
cally evaluated for liver metastasis. A, Typical 
photomicrographs of liver sections stained 
immunohistochemically with anti - PCNA mAb. 
 B, The number of PCNA positive cells analyzed 
by a computer-associated image analysis system. 
*p<0.01 by one factor ANOVA with Scheffe's F 
test. Data represent mean±SD obtained with 5 
mice. Representative results from three similar 
experiments were shown.
Rat IgG LAD-4
Anti LFA-1
　Fig. 2. 
Quantification of whole liver metastasis. Mice 
received injections of RL♂1 cells and each 
antibody as in Fig.1. A, Forward and side 
scattergrams of RL♂1 cells, spleen cells, and cell 
suspensions prepared from the liver of tumor 
bearing mice (lower panels). RL♂1 cells dis-
tributed in gate R1 and spleen cells in gate R3. 
This gate setting was used for analyzing cell 
suspensions from the tumor-bearing liver. 
B, Summary of the flow cytometric analysis. Data 
represent mean±SD obtained with 5 mice. 
*p<0.01 by one factor ANOVA with Scheffe’s F 
test. Representative results from two similar 
experiments were shown.
B
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debris in R2 (Fig.2A).  The FACS data showed 
that LAD-4 significantly inhibited whole liver 
metastasis to the same extent as anti-LFA-1 
mAb (Fig.2B).
Effect of LAD-4 Administration on Survival.
　In the first experiment, mice were injected 
s.c. with RL♂1 cells and i.p. with antibodies as 
described above. Survival did not differ 
significantly among the three groups (Fig.3A).  
In the second experiment, the effect of LAD-4 
administration on the survival of mice 
inoculated i.v. with lymphoma cells was 
examined.  Mice that received LAD-4 survived 
significantly longer than control mice 
(p<0.01), as shown in Fig. 3B. Furthermore, 
LAD-4 administration significantly reduced 
the liver weight of mice inoculated i.v., but not 
s.c., with lymphoma cells, (inoculated i.v.: 
control IgG vs LAD-4＝3.7±0.4 g vs 2.7±0.3 
g, p<0.01; inoculated s.c.: 1.5±0.2 g vs 1.49±
0.2 g, N.S.).  Postmortem examination revealed 
that mice inoculated s.c. with lymphoma cells 
died as a result direct invasion of the 
retroperitoneum involving the intestine, where-
as those inoculated i.v. died as a result of 
diffuse metastasis in the lungs, liver, and 
kidneys (data not shown). Therefore, I 
concluded that reduction of hepatic metastasis 
by LAD-4 administration led to prolongation of 
survival in mice inoculated i.v., but not s.c., 
with lymphoma cells. 
LAD-4 Inhibited Proliferation of RL♂1 
Cells in Vitro.
　In preliminary experiments, we found that 
LAD-4 in a soluble form, but not in a fixed 
form adsorbed on the microtest plate, triggered 
homotypic aggregation of RL♂1 cells.  As this 
effect of LAD-4 is similar to that of an anti-β1-
integrin mAb16) and the integrin family of cell 
adhesion receptors can transduce signals that 
modulate cell growth and differentiation10), I 
examined whether LAD-4 inhibited prolifera-
tion of RL♂1 cells and induced apoptosis in 
vitro. RL♂1 cells were cultured in the 
presence of normal rat IgG, anti-LFA-1 mAb, 
or LAD-4 and the numbers of viable cells were 
determined by a colorimetric assay.  LAD-4 
significantly inhibited RL♂1 cell proliferation 
in a dose-dependent manner, whereas the anti-
LFA-1 mAb (M17/4) did not (Fig.4A).  FN 
adsorbed on the microtest plate did not 
downregulate RL♂1 cell proliferation under 
serum-free conditions, whereas LAD-4 ad-
　Fig. 3.
Kinetics of survival of mice given injections of 
RL♂1 cells and various antibodies. A, Mice were 
injected with i.p. with normal rat IgG (○), LAD-4 
(□), or anti-LFA-1 mAb (▲) after s.c. tumor 
challenge as in Fig.1. B, Mice were injected with 
each antibody as in A after i.v. tumor challenge. 
*p<0.003 by Breslow-Gehan-Wilcoxn test. Repre-
sentative data of two similar experiments are 
shown.
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sorbed on the microtest plate did. (Fig.4B) 
LAD-4 Enhanced AnnexinⅤ Positivity of 
the RL♂1 Cell Population.
　To determine whether LAD-4 could influ-
ence apoptotic cell death, RL♂1 cells were 
cultured in the presence of LAD-4 or control 
antibodies and the percentages of cells un-
dergoing apoptosis were determined by An-
nexinⅤ binding. The proportions of Annexin
Ⅴ-positive/PI negative cells increased from the 
control value of 4% to 24% of total RL♂1 cell 
population after treatment with LAD-4 for 3h, 
whereas no such increase occurred after 
treatment with the anti-LAF-1 mAb or anti-
CD44 mAb (Fig.5A).  The number of Annexin
Ⅴ＋ (apoptotic) cells increased in a time-
dependent manner (Fig.5B), suggesting that 
LAD-4-mediated growth inhibition was related 
to apoptosis of RL♂1 cells.
 
　Fig. 4. 
Downregulation of in vitro proliferation of RL♂1 
cells by LAD-4. A, cells were cultured in the 
presence of the indicated doses of normal rat IgG 
(○), LAD-4 (□), or anti-LFA-1 mAb (▲) at 37℃ 
for 24h or 48h. B, Cells were cultured in a well of 
tissue culture plate coated with LAD-4 (□), 
laminin (◇) or fibronectin (●) at 37℃ for 24h. 
Dotted lines indicate the initial number of cells in 
each assay. The numbers of viable cells were 
calculated with absorbance values of standard 
(known cell numbers). The results are the mean±
SD of three separate experiments with triplicate 
determinations in each experiment. *p<0.01 by 
one factor ANOVA with Scheffe’s F test.
　Fig. 5. 
Increase in AnnexinⅤ-positivity of RL♂1 cells by 
LAD-4. A, Annexin V and propidium iodide (PI) 
staining of RL♂1 cells treated with the indicated 
mAbs (20μg/ml) for 3h. The percentage of 
Annexin V+/PI-cells (early apoptotic cells) is 
indicated in the lower right quadrant. B, The 
percentage of Annexin V+ cells after 3h, 24h or 
48h treatment with normal rat IgG (○), LAD-4 
(□), or anti-LFA-1 mAb (▲). Representative data 
from three similar experiments are shown.
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LAD-4 Induced Activation of Caspase-3 
in RL♂1 Cells.
　To determine whether the observed Annexin
Ⅴ binding increases other well-characterized 
markers of apoptosis, I performed a colorimet-
ric assay to measure the caspase-3 activities of 
RL♂1 cells after treatment with LAD-4 or the 
anti-LFA-1 mAb. Induction of caspase-3 activa-
tion by LAD-4 was observed after treatment 
for 3h and this effect was dependent on the 
dose of LAD-4 added to the culture (Fig.6A), 
whereas no effect was observed with the anti-
LFA-1 mAb (M17/4) (Fig.6B).  After treatment 
with LAD-4 for 24h, the caspase-3 activity was 
not significantly higher than the control value 
and was lower than that induced by cyclo-
phosphamide (Fig.6B).
　I performed western blotting to verify these 
results and demonstrated that caspase-3 
activation was accompanied by cleavage of a 
36-kDa procaspase-3 to an active 17-kDa 
fragment during LAD-4-induced apoptosis. 
The intensity of the 17-kDa cleaved caspase-3 
band increased in a time- dependent manner, 
while that of the 36-kDa procasapse-3 band 
decreased slightly with time (Fig.7).
　Fig. 6. 
LAD-4-induced caspase-3 activation determined 
by a colorimetric assay. 
A, Cells were cultured for 3h with the indicated 
concentration of LAD-4 (□) or normal rat IgG 
(○). 10 mM of cyclophosphamide (CY) (▼) was 
employed as a positive control. The value of the 
inhibitor sample with Ac-DEVD-CHO was sub-
tracted from that of the noninhibited sample. 
Representative data from two similar experi-
ments with duplicate determinations are shown. 
B, Cells were cultured for 3h or 24h with 50μg/ml 
of the indicated antibodies or 5 mM of CY. Data 
represent the mean±SD of three separate 
experiments with duplicate determinations. 
*p<0.05, **p<0.01 by one factor ANOVA with 
Scheffe’s F test.
　Fig. 7.
LAD-4-induced caspase-3 cleavage determined by 
Western blotting. Cells were treated with LAD-4 
(50μg/ml) for the indicated times and lysates (40 
μg) were analyzed by immunoblotting using anti-
caspase-3 (upper panel) Ab, or anti-cleaved 
caspase-3 Ab (lower panel). Representative data 
from two similar experiments are shown.
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LAD-4 Increased Apoptotic DNA Fragmen-
tation in RL♂1 Cells.
　I analyzed LAD-4-treated cells for apoptotic 
DNA fragmentation by the TUNEL assay. The 
percentage of TUNEL positive cells was 
approximately 6% to 36% after treating with 
3h and 24h, respectively, whereas only 
marginal effect was observed with anti-LFA-1 
mAb (Fig.8). These results demonstrated that 
LAD-4 gradually induced apoptosis of RL♂1 
cells.
DISCUSSION
　My results show that LAD-4, which re-
cognizes a new FN receptor, inhibits liver 
metastasis by RL♂1 lymphoma cells in vivo. 
 Several mechanisms governing the inhibition 
of liver metastasis have been proposed. 
 Lymphoma cells inoculated either s.c. or i.v. 
are thought to disseminate through the 
bloodstream and accumulate in the preferred 
organs such as the liver, spleen, and kid-
neys9),17). Receptor occupancy by LAD-4 has 
been reported to inhibit the adhesion of RL♂1 
cells to hepatocytic FN and to partially inhibit 
accumulation of these cells in the liver6).  This 
mechanism may be involved in partial in-
hibition of metastasis formation in the liver 2 
to 3 weeks after tumor inoculation.
　Surprisingly, our data showed clearly that 
LAD-4 induced apoptosis of RL♂1 cells in 
vitro, i.e., expression of phosphatidylserine 
detected by Annexin Ⅴ binding, caspase-3 
activation, and apoptotic DNA fragmentation, 
and that LAD-4 downregulated RL♂1 cell 
proliferation.  As FN adsorbed on the microtest 
plates neither induced caspase-3 activation nor 
downregulated RL♂1 cell proliferation, homo-
typic aggregation of RL♂1 cells and/or cross-
linking of the receptor molecules triggered by 
LAD-4 may transduce a death signal. The later 
mechanism may also contribute to inhibition of 
liver metastasis.  Another possible mechanism 
of the anti-tumor effect of LAD-4 is antibody-
mediated cellular cytotoxicity (ADCC), as 
reported with an anti - CD20 mAb18),19),20). 
However, I performed a 4h 51Cr-release assay 
on spleen cells and detected no ADCC (data not 
shown), suggesting that ADCC contributed 
little or nothing to the anti-metastatic effect of 
LAD-4.
　Integrin receptors mediate not only cell 
adhesion but also signal transduction through 
focal adhesion kinase21).  It has been reported 
that integrin receptor occupancy by its ligand 
transduces signals leading to cell growth10) and, 
　Fig. 8.
Quantification of apoptotic DNA fragmentation 
by TUNEL assay.  5 × 106 cells were cultured in 
the presence of normal rat IgG, LAD-4 or anti-
LFA-1 mAb (100μg/ml) for 3h or 24h at 37℃. 
Cells were treated with TdT and stained with 
FITC-dUTP. The percentage of TUNEL-positive 
cells is presented for each panel. Representative 
data from three similar experiments are shown.
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furthermore, adhesion of small cell carcinomas 
of the lung to extracellular matrix protein 
confers resistance to chemotherapeutic agents 
as a result of β1-integrin-stimulated tyrosine 
kinase activation22). In agreement with these 
reports, binding of RL♂1 cells to fixed FN did 
not downregulate, but actually upregulated RL
♂1 cell proliferation (Fig.4B).  Although LAD-
4 may have therapeutic potential by virtue of 
effect on survival of mice inoculated with 
lymphoma cells, it was not curative.  This may 
be because LAD-4 administered i.p. was 
absorbed  by circulating leukocytes bearing the 
antigenic molecule and consequently, the 
amount of LAD-4 that reached the lymphoma 
cells was not enough to induce apoptosis. 
 Another explanation is that anti-apoptotic 
factors, such as survivin that inhibit caspase 
activity 23),24) may have been present. Although 
the precise mechanisms responsible for LAD-4-
induced apoptosis are unknown, the combina-
tion of LAD-4 with a survival factor inhibitor, 
such as anti-sense survivin oligonucleotides, 
may have a therapeutic effect against lym-
phomas.
　In conclusion, LAD-4 partially but signifi-
cantly inhibited liver metastasis by RL♂1 
lymphoma cells. One of the mechanisms 
responsible for this effect may be induction of 
lymphoma cell apoptosis, which may be 
initiated through cross-linking of the receptor 
molecules by LAD-4.
　I thank Dr. Shigemi Fuyama at Oitama 
General Hospital for providing ascites cell line 
of RL♂1 and Dr. Yuji Takeda at Department of 
Immunology and Parasitology for advice on 
FACS analysis.
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